top of page
Search
Compass Pathways Discloses New Results for Its Synthetic Psilocybin Patent for Treatment-Resistant Depression; Promises Commercialisation by Year-End
r Compass Pathways, the British psychedelic technology innovation company, announced this past February 17, 2026, the new results from its second Phase 3 research trial. The study evaluated the use of COMP360 (the company’s patented synthetic version of psilocybin) for the treatment of resistant depression. The two Phase 3 trials (COMP005 and COMP006) utilised COMP360 in a total of over 800 patients. The company claims it is ready to commercialize the substance by the end of
Iago Lôbo
Feb 232 min read
PSILOCYBIN NEWS
If LSD was the key molecule for the birth of Psychedelic Science in the 1950s, some say psilocybin is the molecule of the Psychedelic Renaissance. Warming up the engines for this month's CAMP.educ module meetings on "Psilocybin and Psilocybin-Assisted Psychotherapy" (February 28th and March 1st, 2026), we decided to bring you some updates on this molecule in the current psychedelic landscape. It is worth remembering that at the dawn of Psychedelic Science, psilocybin was not
Iago Lôbo
Feb 113 min read
bottom of page